At the June 2025 sale hearing 23andMe had about 13 million customers, and more than 80% of them had chosen to take part in its medical-research programmes.
about 13 million customers, more than 80% in research programmes
Dated 27 Jun 2025Source checked 19 Oct 2026Page out of reach at the last check, 21 Oct 2026Basis: docket
In the source's own words
“and they currently have approximately 13 million customers. More than 80% of the Debtors’ customers also have elected to participate in the Debtors’ medical-research programs.”
Where it was read
Also read from the same source
- Substantially all assets of 23andMe Holding Co. (direct-to-consumer genetic testing business, about 13 million customers, genetic and other personal data, medical research programme), sold to TTAM Research Institute in Chapter 11 under section 363. The price is for the whole business, not the data alone.
- Substantially all assets of 23andMe Holding Co. (about 13 million customers' genetic and other personal data, laboratory, brand), Regeneron Pharmaceuticals' bid that won the three-day May 2025 auction (seven bidders, opening bid $52 million) and was later topped
- Treat the first bid on a distressed data asset as a floor and insist on an open auction
- In re 23andMe Holding Co.: memorandum opinion approving the sale to TTAM Research Institute (June 27, 2025) (In re 23andMe Holding Co., et al., No. 25-40976-357 (Bankr. E.D. Mo.), Memorandum Opinion, ECF No. 908 (June 27, 2025))
- In re 23andMe Holding Co.: section 363(b)(1) does not let a debtor ignore state data-transfer laws (June 27, 2025) (In re 23andMe Holding Co., et al., No. 25-40976-357 (Bankr. E.D. Mo.), Memorandum Opinion, ECF No. 908 (June 27, 2025))
- In re 23andMe Holding Co.: which privacy policy counts under section 363(b)(1) (June 27, 2025) (In re 23andMe Holding Co., et al., No. 25-40976-357 (Bankr. E.D. Mo.), Memorandum Opinion, ECF No. 908 (June 27, 2025))
What it is about
Figures it counts in
It is shown on its own, not counted into a figure.